Krensavage Asset Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-308,478
| Closed | -$2.68M | – | 15 |
|
|
2018
Q2 | $2.68M | Sell |
308,478
-24,360
| -7% | -$219K | 0.69% | 13 |
|
|
2018
Q1 | $3.38M | Sell |
332,838
-107,264
| -24% | -$901K | 0.82% | 14 |
|
|
2017
Q4 | $2.13M | Buy |
440,102
+196,974
| +81% | +$958K | 0.67% | 14 |
|
|
2017
Q3 | $1.11M | Hold |
243,128
| – | – | 0.34% | 14 |
|
|
2017
Q2 | $1.23M | Hold |
243,128
| – | – | 0.37% | 15 |
|
|
2017
Q1 | $1.16M | Sell |
243,128
-47,725
| -16% | -$241K | 0.37% | 15 |
|
|
2016
Q4 | $1.63M | Buy |
290,853
+2,559
| +0.9% | +$14K | 0.58% | 16 |
|
|
2016
Q3 | $1.6M | Buy |
288,294
+539
| +0.2% | +$3.56K | 0.58% | 17 |
|
|
2016
Q2 | $2.02M | Buy |
287,755
+788
| +0.3% | +$5.55K | 0.73% | 20 |
|
|
2016
Q1 | $1.9M | Sell |
286,967
-1,359
| -0.5% | -$10K | 0.68% | 21 |
|
|
2015
Q4 | $2.97M | Buy |
288,326
+8,609
| +3% | +$99.8K | 0.95% | 20 |
|
|
2015
Q3 | $3.29M | Sell |
279,717
-47,900
| -15% | -$529K | 1.19% | 20 |
|
|
2015
Q2 | $3M | Buy |
327,617
+11,468
| +4% | +$86.6K | 1.13% | 20 |
|
|
2015
Q1 | $1.96M | Hold |
316,149
| – | – | 0.89% | 21 |
|
|
2014
Q4 | $1.77M | Buy |
+316,149
| New | +$1.84M | 0.99% | 22 |
|
Krensavage Asset Management's JNP Position: Q3 2018 in Review
Krensavage Asset Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 308,478 shares — an estimated $2.68M sold.
Krensavage Asset Management first reported a position in JNP in Q4 2014 and held it in 15 quarters. The position peaked at $3.38M in Q1 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Krensavage Asset Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Krensavage Asset Management sold 308,478 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $2.68M.
- Krensavage Asset Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
- Krensavage Asset Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $3.38M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Krensavage Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.